News About: Pharm. Affairs


TYLENOL may cause liver damages if taking more than 4,000mg a day

It was studied that drugs containing acetaminophen, such as analgesic/antipyretic TYLENOL, had a high chance to cause liver damages if being taken by patients with a volume higher than 4,000mg a day. Thus, approval d...

“In Korean CSO market are about 4 thousand private business owners”

“The number of private business owners is estimated at approximately 3 to 4 thousand in the Korean pharmaceutical market. Some think in the market are over 20 thousand business owners. In order for the Korean CSO mark...

Prostatic cancer treatments ‘Jevtana’ and ‘Zytiga’ newly registered in list of health insurance benefits this May

104 products, such as Jevtana and Zytiga, prostate cancer therapies, will be newly registered in the list of health insurance benefits this May. The Ministry of Health and Welfare(MOHW) revised and placed the ‘Drug I...

Hanmi Pharm’s innovative anticancer drug ‘Posiotinib’ published in international SCI journal

A research result of Poziotinib, a targeted therapy for cancer developed by Hanmi Pharm, was registered in the online version of Nature Medicine, an international SCI(Science Citation Index) journal. Spectrum Pharmac...

59% of members in KPA were women pharmacists

While the ratio of women pharmacists is getting higher and higher, 59% of members in the Korea Pharmaceutical Association(KPA) reportedly were female pharmacists. According to the Korea Pharmaceutical Association Sta...

Psoriatic arthritis therapy ‘Guselkumab’ acquires approval in Korea

‘Guselkumab(product name: Tremfya Prefilled Syringe Inj),’ a Janssen’s psoriasis & arthritis therapy, acquired approval in Korea. The Ministry of Food and Drug Safety(MFDS) decided new drug approval on ‘Tremfya Prefi...

Which are new drugs approved this 1st quarter?

4 new drugs including ‘Aljaview Inj,’ a FutureChem’s diagnostic drug for Alzheimer’s disease, reportedly acquire approval in the last 1st quarter. According to the Ministry of Food and Drug Safety’s Online Drug Libra...

Samsung Bioepis agrees on ‘SB5’ patent conflict with AbbVie

Samsung Bioepis(CEO/President Han-Seung Ko) agreed on the patent conflict about SB5(generic name: adalimumab, biosimilar referencing Humira), a biosimilar for the treatment of autoimmune disease(Anti-TNF-α). Samsung ...

Bsivo enters Samsung Medical Center after Severance and Seoul National University Hospital

‘Besivo Tab,’ an Ildong Pharmaceutical’s new chronic hepatitis B treatment, landed in Samsung Medical Center. ‘Besivo’ is increasing a chance to enlarge its market by entering major general hospitals from Severance H...

‘Dupilumab,’ moderate-to-severe eczema therapy, lands in Korea

‘Dupilumab,’ a moderate-to-severe eczema treatment for adults, will land in the Korean market. As of 30 March, the Ministry of Food and Drug Safety(MFDS) approved Sanofi-Aventis Korea’s ‘Dupixent Prefilled Inj 300mg(...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.